Xiaorui Yao
Overview
Explore the profile of Xiaorui Yao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang M, Yao X, Xia F, Xiang S, Tang W, Zhou B
BMC Complement Med Ther
. 2024 Jan;
24(1):36.
PMID: 38216941
Background: Endoplasmic reticulum (ER) stress, promoting lipid metabolism disorders and steatohepatitis, contributes significantly to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Hugan Qingzhi tablets (HQT) has a definite effect...
2.
Yang M, Chen Z, Xiang S, Xia F, Tang W, Yao X, et al.
BMC Complement Med Ther
. 2020 Dec;
20(1):377.
PMID: 33308192
Background: Previous studies have found that Hugan Qingzhi tablet (HQT) has significant lipid-lowering and antioxidant effects on non-alcoholic fatty liver disease (NAFLD). Moreover, the results of proteomic analysis confirmed that...
3.
Tang W, Yao X, Xia F, Yang M, Chen Z, Zhou B, et al.
Oxid Med Cell Longev
. 2019 Jan;
2018:7261619.
PMID: 30671174
Background: Accumulative evidence showed that gut microbiota was important in regulating the development of nonalcoholic fatty liver disease (NAFLD). Hugan Qingzhi tablet (HQT), a lipid-lowering and anti-inflammatory medicinal formula, has...
4.
Yao X, Xia F, Tang W, Xiao C, Yang M, Zhou B
Data Brief
. 2017 Nov;
15:612-614.
PMID: 29085877
The data presented in this article are related to the research article entitled "Isobarictags for relative and absolute quantitation (iTRAQ) -based proteomics for the investigation of the effect of HuganQingzhi...
5.
Yao X, Xia F, Tang W, Xiao C, Yang M, Zhou B
J Ethnopharmacol
. 2017 Oct;
212:208-215.
PMID: 29031784
Ethnopharmacological Relevance: Hugan Qingzhi tablet (HQT), a traditional Chinese medicine formula has been adopted for preventing and treating nonalcoholic fatty liver disease (NAFLD). Aim: In order to explore the anti-NAFLD...
6.
Xia F, Yao X, Tang W, Xiao C, Yang M, Zhou B
Front Pharmacol
. 2017 Mar;
8:99.
PMID: 28293193
In previous research, Hugan Qingzhi, a traditional Chinese medicine, was shown to have protective effects against hepatic steatosis. However, its activity against non-alcoholic fatty liver disease (NAFLD) and the mechanisms...
7.
Zeng L, Tang W, Yin J, Feng L, Li Y, Yao X, et al.
Cell Physiol Biochem
. 2016 Nov;
40(3-4):453-464.
PMID: 27889747
Background: Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic disorders including hepatic lipid accumulation and inflammation. Alisol A 24-acetate, a triterpene from Alismatis rhizome, has multiple biologic activities...
8.
Liu J, Yao X, Lu J, Qiao X, Liu Z, Li S
Environ Sci Pollut Res Int
. 2015 Nov;
23(6):5892-901.
PMID: 26593726
This study investigated the concentrations and distribution of eight sterol compounds in the surface sediments of Bosten Lake and Manas Lake, Xinjiang, China. The ratios of sterols as diagnostic indices...
9.
Tang W, Zeng L, Yin J, Yao Y, Feng L, Yao X, et al.
Evid Based Complement Alternat Med
. 2015 Jul;
2015:810369.
PMID: 26146507
Ethnopharmacological Relevance. The Hugan Qingzhi tablet (HQT) is a traditional Chinese medicine used for treating NAFLD (nonalcoholic fatty liver disease). The present study evaluated the anti-inflammatory effects of HQT in...
10.
Forest T, Holder D, Smith A, Cunningham C, Yao X, Dey M, et al.
Endocrinology
. 2014 Jan;
155(3):783-92.
PMID: 24424056
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor-based incretin therapy intended for the treatment of type 2 diabetes mellitus (T2DM), has not been linked to adverse effects on the pancreas in prospective...